Inclusion Criteria:~1. Male or post menopausal female patients aged â‰§50 years old;~2. The informed consent
must be signed by the patient and co-signed by their proxy or principal caregivers before undergoing any study
procedures;~3. Probable Alzheimer's disease based on the National Institute of Neurological and Communicative
Disorders and Alzheimer's dementia and related disorder (NINCDS-ADRDA)~4. Patients with Mini-Mental State
Examination (MMSE) scores of 12\~24~5. Patients with Clinical Dementia Rating (CDR)in mild (CDR = 1) and
moderate (CDR = 2) AD~6. Cranial computed tomography (CT) or brain magnetic resonance imaging (MRI) must be
within the past 12 months;~7. Patients must be able to complete baseline assessments;~8. An eligible principal
caregiver must be able to accompany the patient to all scheduled visits;~9. Patients currently taking ChEIs
such as donepezil, rivastigmine, or galantamine are allowed if the dose has been unchanged for the last 3
months before the study entry.~
